FindTrial
Sign In

The clinical efficacy of endoscopic lumbar interbody fusion in the treatment of lumbar spondylolisthesis

The clinical efficacy of endoscopic lumbar interbody fusion in the treatment of lumbar spondylolisthesis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100050038
Enrollment
Unknown
Registered
2021-08-16
Start date
2021-08-27
Completion date
Unknown
Last updated
2022-04-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lumbar spondylolisthesis

Interventions

control group vs experimental group:No

Sponsors

The Affiliated Hospital of Qingdao University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
48 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Single-segment degenerative or isthmic lumbar spondylolisthesis (Meyerding I/II grade); 2. Neurogenic claudication caused by unilateral recess stenosis; 3. Instability during clinical and radiological examinations; 4. Neurological symptoms (including low back pain, sciatica, neurogenic claudication and limb symptoms) have not been relieved after conservative treatment for more than 6 months.

Exclusion criteria

Exclusion criteria: 1. Previous lumbar fusion surgery; 2. Severe central canal stenosis or bilateral recess stenosis; 3. Serious diseases, such as head trauma, arachnoiditis, active infection or spinal metastasis; 4. Severe osteoporosis.

Design outcomes

Primary

MeasureTime frame
Intraoperative fluoroscopy times;Operative Time;—

Countries

China

Contacts

Public ContactZhou Chuanli

The Affiliated Hospital of Qingdao University

maxuexiaospinal@163.com+86 18661809796

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026